Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects gemcitabine plus capecitabine has on
patients with pancreatic or biliary cancer, and to determine the optimal dose that can be
given safely of these two drugs together (called the maximum tolerated dose). Gemcitabine and
capecitabine are two chemotherapy drugs used to treat pancreatic and biliary cancer. These
two drugs used together are considered an acceptable standard of care for pancreatic and
biliary cancers. However, in this study the dose and dosing schedule will be changed, in the
hopes that the drugs will have more effect with fewer side effects than when given in the
standard way.